<DOC>
	<DOCNO>NCT00367991</DOCNO>
	<brief_summary>The purpose study see naturally-occurring hormone call erythropoietin change action platelet blood . Patients heart attack treat medicine reduce clot action platelet . This study try determine whether erythropoietin alters clot action platelet patient receive anti-platelet medicine . It important understand effect erythropoietin platelet since preliminary study animal suggest erythropoietin may protect heart damage heart attack .</brief_summary>
	<brief_title>Effects Recombinant Human Erythropoietin Platelet Function Patients With Acute Myocardial Infarction</brief_title>
	<detailed_description>Anti-apoptotic effect erythropoietin experimental myocardial infarction ( MI ) ischemia-reperfusion injury suggest potential therapeutic benefit patient acute MI . Before therapeutic potential recombinant human erythropoietin ( rHuEpo ) acute MI test large clinical trial , information effect short-term rHuEpo platelet function need . Accordingly , current proposal aim determine effect rHuEpo ( dose previously show inhibit anti-platelet effect aspirin clopidogrel healthy subject ) platelet function safety measure measure infarct size patient acute coronary syndrome receive clinically-indicated standard anti-platelet therapy aspirin , clopidogrel glycoprotein Iib-IIIa inhibitor . Specific Aim 1 : To determine effect intravenous rHuEpo 400 U/kg daily 3 day vs. placebo vivo vitro platelet function patient acute MI undergo percutaneous revascularization . Specific Aim 2 : To obtain pilot data estimate effect administration rHuEpo 400 U/kg daily 3 day vs. placebo biochemical marker myocardial infarction size leave ventricular ejection fraction patient acute MI undergo percutaneous revascularization</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Age 2175 year Clinical evidence acute myocardial infarction ( MI ) total subtotal occlusion angiogram Status post percutaneous revascularization procedure acute MI TIMI 3 flow Ongoing clinicallyindicated treatment aspirin , thienopyridines Hemodynamic instability/shock severe congestive heart failure Time onset chest pain revascularization procedure &gt; 16 hour Use intravenous thrombolytic agent treatment MI Known need additional revascularization procedure</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Platelet function test</keyword>
	<keyword>Erythropoietin</keyword>
	<keyword>Myocardial infarction</keyword>
</DOC>